Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin in Refractory Rheumatoid Arthritis
ChiCTR-IPR-17010307Phase 4Recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in Refractory rheumatoid arthritis (RRA) (2 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoints: Peripheral blood lymphocyte subsets, CD4+ T cell subgroups and 2 more. Started Dec 2016; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Refractory rheumatoid arthritis (RRA)
Beyond the preview
Go deeper on ChiCTR-IPR-17010307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010307.